STABLE-MATES
Phase 3 Recruiting
272 enrolled
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines
Phase NA Recruiting
800 enrolled
KAT6
Phase 2 Recruiting
320 enrolled
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2 Recruiting
110 enrolled
AIRTECH
Phase NA Recruiting
240 enrolled
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Phase 2 Recruiting
50 enrolled
LIMITLESS
Phase 3 Recruiting
30 enrolled
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase 1 Recruiting
30 enrolled
DeLLphi-312
Phase 3 Recruiting
330 enrolled
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
Phase 2 Recruiting
29 enrolled
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Phase 3 Recruiting
480 enrolled
Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes
Recruiting
75 enrolled
PSI-Immune
Phase 2 Recruiting
880 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Phase 2 Recruiting
46 enrolled
Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners
Phase NA Recruiting
300 enrolled
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Recruiting
150 enrolled
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
Phase NA Recruiting
400 enrolled
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2 Recruiting
170 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Phase 3 Recruiting
304 enrolled
DeLLphi-306
Phase 3 Recruiting
400 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 Recruiting
350 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Phase 1 Recruiting
240 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
INSPIRE-CRT
Phase NA Recruiting
100 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
460 enrolled
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Phase 1/2 Recruiting
594 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Phase 2 Recruiting
156 enrolled
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 Recruiting
364 enrolled
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Phase 2 Recruiting
535 enrolled
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Phase 3 Recruiting
750 enrolled
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Phase 1 Recruiting
145 enrolled
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/2 Recruiting
150 enrolled
Evaluation for NCI Surgery Branch Clinical Research Protocols
Recruiting
7,000 enrolled
Collection of Blood From Patients With Cancer
Recruiting
1,750 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Recruiting
2,000 enrolled
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Recruiting
500 enrolled
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 Recruiting
46 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled